Ivabradina Alter

Ivabradine, the active ingredient in Ivabradina Alter, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction, improving symptoms and exercise capacity.

GNH USA supplies Ivabradina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is available for bulk distribution to healthcare providers across multiple regions.

Ivabradina Alter acts on the cardiac If channel to lower heart rate in several cardiovascular conditions.

- Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers resting heart rate, alleviates symptoms and may decrease hospitalization risk. - Patients intolerant to beta‑blockers: provides heart‑rate reduction without beta‑adrenergic blockade, offering an alternative therapeutic option.

Ivabradina Alter may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate may fall below 60 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness, especially on standing.

Serious or Rare Side Effects: - Symptomatic bradycardia: may cause fatigue, syncope or hypotension. - Atrial fibrillation: new‑onset irregular rhythm. - Severe hypotension: marked drop in blood pressure requiring medical attention. - Allergic reactions: rash, pruritus or anaphylaxis in rare cases.

Before prescribing Ivabradina Alter, clinicians should consider several precautionary measures to ensure patient safety. - Heart rate monitoring: avoid use in patients with resting heart rate below 60 bpm. - Conduction disorders: caution in individuals with sick sinus syndrome or second‑degree AV block. - Hepatic impairment: dose adjustment may be required in severe liver disease. - Concomitant bradycardic agents: monitor closely when combined with beta‑blockers, calcium‑channel blockers or digoxin. - CYP3A4 inhibitors: avoid strong inhibitors; moderate inhibitors require dose reduction. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Ivabradina Alter can interact with other medicines, influencing its plasma concentration or additive cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine exposure. - Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, diltiazem, verapamil): risk of excessive bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may raise ivabradine levels modestly. - Drugs affecting cardiac conduction (e.g., digoxin, amiodarone): may enhance bradyarrhythmic risk. - QT‑prolonging agents: combined use may increase arrhythmia potential.